---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-010965"
form_type: "8-K/A"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2026-02-05T23:59:59+00:00"
generated_at: "2026-05-16T04:17:51.432788+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools completes sale of SomaScan business to Illumina for ~$363.7M net cash

## Summary
- Net cash proceeds of ~$363.7M from sale of SomaLogic and Sengenics entities to Illumina.
- Potential earnout payments up to $75M based on 2025/2026 revenue milestones.
- Pro forma cash and equivalents of $478.3M as of Sep 30, 2025; gain on sale of $161.9M.
- Company retains mass cytometry and microfluidics businesses; no longer party to Collaboration Agreement.
- Transaction expenses of $18.4M incurred; $14.8M paid at closing.

## SEC filing metadata
- accession: 0001104659-26-010965
- form_type: 8-K/A
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2026-02-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000110465926010965/0001104659-26-010965-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000110465926010965/tm265294d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-010965
- JSON: https://secwatch.observer/filing/0001104659-26-010965.json
- Plain text: https://secwatch.observer/filing/0001104659-26-010965.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.